Kerwin Bruce A, Remmele Richard L
Department of Protein Pharmaceutics, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA.
J Pharm Sci. 2007 Jun;96(6):1468-79. doi: 10.1002/jps.20815.
The exposure of proteins to light and the ensuing chemical and physical degradation has been studied extensively for many years. The residues in proteins that undergo primary photooxidation include tryptophan, tyrosine, phenylalanine, and cysteine/cystine. While photooxidation has been recognized as a major contributor to protein degradation, the effects of photoinduced damage have not been widely studied for biopharmaceuticals. This is particularly important since photodegradation can lead to changes in primary, secondary, and tertiary structures of protein and these changes, while not definitively established, could lead to differences in long-term stability, bioactivity, or immunogenicity. In this review we briefly describe the major pathways of photodegradation for proteins followed by a description of the limited data on photodegradation of biopharmaceuticals and methods that have been used to reduce or prevent damage. It is our intent to spur additional research in this area for increasing the safety and effectiveness of biopharmaceutical products.
蛋白质对光的暴露以及随之而来的化学和物理降解已经被广泛研究多年。蛋白质中经历初级光氧化的残基包括色氨酸、酪氨酸、苯丙氨酸和半胱氨酸/胱氨酸。虽然光氧化已被认为是蛋白质降解的主要因素,但光诱导损伤对生物制药的影响尚未得到广泛研究。这一点尤为重要,因为光降解会导致蛋白质一级、二级和三级结构的变化,而这些变化虽然尚未明确确定,但可能会导致长期稳定性、生物活性或免疫原性的差异。在这篇综述中,我们简要描述了蛋白质光降解的主要途径,随后介绍了关于生物制药光降解的有限数据以及用于减少或防止损伤的方法。我们的目的是推动该领域的更多研究,以提高生物制药产品的安全性和有效性。